UA110696C2 - 7-[3,5-дигідрокси-2-(3-гідрокси-5-фенілпент-1-еніл)циклопентил]-n-етилгепт-5-енамід (біматопрост) у кристалічній формі ii, спосіб його одержання й спосіб його застосування - Google Patents

7-[3,5-дигідрокси-2-(3-гідрокси-5-фенілпент-1-еніл)циклопентил]-n-етилгепт-5-енамід (біматопрост) у кристалічній формі ii, спосіб його одержання й спосіб його застосування

Info

Publication number
UA110696C2
UA110696C2 UAA201207505A UAA201207505A UA110696C2 UA 110696 C2 UA110696 C2 UA 110696C2 UA A201207505 A UAA201207505 A UA A201207505A UA A201207505 A UAA201207505 A UA A201207505A UA 110696 C2 UA110696 C2 UA 110696C2
Authority
UA
Ukraine
Prior art keywords
crystalline form
bimatoprost
fenilpen
etylhept
dyhidroksy
Prior art date
Application number
UAA201207505A
Other languages
English (en)
Inventor
Дьйорді Ф. Амбрус
Кімарс Карамі
Ке ВУ
Original Assignee
Аллерган, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43639099&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA110696(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Аллерган, Інк. filed Critical Аллерган, Інк.
Publication of UA110696C2 publication Critical patent/UA110696C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/39—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

У даному винаході представлена нова кристалічна форма біматопросту, позначена як кристалічна форма II.Ця нова кристалічна форма є найбільш стійкою з відомих на сьогоднішній день форм біматопросту.Більше того, було виявлено, що біматопрост у кристалічній формі II легко може бути отриманий із кристалічної форми І.
UAA201207505A 2009-11-23 2010-11-19 7-[3,5-дигідрокси-2-(3-гідрокси-5-фенілпент-1-еніл)циклопентил]-n-етилгепт-5-енамід (біматопрост) у кристалічній формі ii, спосіб його одержання й спосіб його застосування UA110696C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26347109P 2009-11-23 2009-11-23
PCT/US2010/057494 WO2011063276A1 (en) 2009-11-23 2010-11-19 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof

Publications (1)

Publication Number Publication Date
UA110696C2 true UA110696C2 (uk) 2016-02-10

Family

ID=43639099

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201207505A UA110696C2 (uk) 2009-11-23 2010-11-19 7-[3,5-дигідрокси-2-(3-гідрокси-5-фенілпент-1-еніл)циклопентил]-n-етилгепт-5-енамід (біматопрост) у кристалічній формі ii, спосіб його одержання й спосіб його застосування

Country Status (19)

Country Link
US (2) US8629185B2 (uk)
EP (1) EP2504313A1 (uk)
JP (2) JP5921439B2 (uk)
KR (1) KR20120085330A (uk)
CN (2) CN102712584B (uk)
AU (1) AU2010321831B2 (uk)
BR (1) BR112012012387A2 (uk)
CA (1) CA2781698A1 (uk)
CL (1) CL2012001339A1 (uk)
CO (1) CO6551754A2 (uk)
HK (1) HK1207570A1 (uk)
IL (2) IL219959A (uk)
IN (1) IN2012DN05209A (uk)
MX (1) MX2012005968A (uk)
NZ (1) NZ600263A (uk)
RU (1) RU2577546C2 (uk)
UA (1) UA110696C2 (uk)
WO (1) WO2011063276A1 (uk)
ZA (1) ZA201203883B (uk)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010321831B2 (en) * 2009-11-23 2016-07-07 Allergan, Inc. 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof
EP2723714B1 (en) * 2011-06-02 2017-06-21 Chinoin Zrt. Novel processes for the preparation of prostaglandin amides
ES2752028T3 (es) 2012-10-26 2020-04-02 Forsight Vision5 Inc Sistema oftálmico para la liberación sostenida del fármaco en el ojo
US11058677B2 (en) * 2012-12-19 2021-07-13 Novartis Ag LFA-1 inhibitor formulations
US9120738B2 (en) * 2012-12-28 2015-09-01 Allergan, Inc. Crystalline forms of bimatoprost acid, methods for preparation, and methods for use thereof
US9447014B2 (en) 2012-12-28 2016-09-20 Allergan, Inc. Tromethamine salt of bimatoprost acid in crystalline form, methods for preparation, and methods for use thereof
US10273206B2 (en) 2014-06-27 2019-04-30 Allergan, Inc. Tromethamine salt of bimatoprost acid in crystalline form 1, methods for preparation, and methods for use thereof
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
CN115677549A (zh) * 2022-10-27 2023-02-03 神隆医药（常熟）有限公司 一种贝美前列素手性异构体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU403156A3 (uk) * 1968-07-29 1973-10-19
US7166730B2 (en) * 2000-01-27 2007-01-23 Fine Tech Laboratories, Ltd Process for the preparation of prostaglandin derivatives
IL143477A (en) * 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
KR20030046395A (ko) * 2000-07-28 2003-06-12 인스파이어 파마슈티컬스 인코퍼레이티드 인돌 유도체를 사용하여 안압을 감소시키는 방법
WO2005066256A1 (en) * 2003-12-30 2005-07-21 Metabolix, Inc. Nucleating agents
IL177762A0 (en) * 2006-08-29 2006-12-31 Arieh Gutman Bimatoprost crystalline form i
AU2010321831B2 (en) * 2009-11-23 2016-07-07 Allergan, Inc. 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof

Also Published As

Publication number Publication date
IL219959A0 (en) 2012-07-31
IL219959A (en) 2015-07-30
IN2012DN05209A (uk) 2015-10-23
JP2016094471A (ja) 2016-05-26
JP5921439B2 (ja) 2016-05-24
HK1207570A1 (en) 2016-02-05
RU2577546C2 (ru) 2016-03-20
NZ600263A (en) 2014-08-29
MX2012005968A (es) 2012-08-15
KR20120085330A (ko) 2012-07-31
EP2504313A1 (en) 2012-10-03
RU2012125185A (ru) 2013-12-27
CN102712584B (zh) 2014-10-29
CA2781698A1 (en) 2011-05-26
AU2010321831A1 (en) 2012-06-21
CL2012001339A1 (es) 2012-08-10
US8629185B2 (en) 2014-01-14
WO2011063276A1 (en) 2011-05-26
BR112012012387A2 (pt) 2019-09-24
JP2013511573A (ja) 2013-04-04
US9181176B2 (en) 2015-11-10
CN102712584A (zh) 2012-10-03
IL239892A0 (en) 2015-08-31
CO6551754A2 (es) 2012-10-31
CN104367580A (zh) 2015-02-25
ZA201203883B (en) 2013-01-31
AU2010321831B2 (en) 2016-07-07
US20140113974A1 (en) 2014-04-24
US20110152376A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
UA110696C2 (uk) 7-[3,5-дигідрокси-2-(3-гідрокси-5-фенілпент-1-еніл)циклопентил]-n-етилгепт-5-енамід (біматопрост) у кристалічній формі ii, спосіб його одержання й спосіб його застосування
CY1123958T1 (el) Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
TR201901886T4 (tr) DNA-PK inhibitörleri.
MY159614A (en) Microorganism producing o-phosphoserine and method of producing l-cysteine or derivatives thereof from o-phosphoserine using the same
SG10201906113RA (en) Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
EA200970580A1 (ru) Таннат разагилина
MX2012007710A (es) Alfa-amilasas.
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
EA201400938A1 (ru) Способ получения 2-(2,3-диметилфенил)-1-пропаналя с использованием хлорацетона
EA201391318A1 (ru) Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение
MX2013009175A (es) Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas.
BR112012017051A2 (pt) método para diminuir a imunogenicidade
UA111827C2 (uk) Спосіб отримання інгенол-3-ангелату
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
MY155330A (en) Methods for salt production
CL2012003491A1 (es) Compuesto derivado de dihidropirrol sustituidos; proceso para preparar dichos derivados en forma estereoselectiva.
EP2557919A4 (en) STABILIZED FORMULATIONS OF STATIN
EA200970126A1 (ru) Способ получения прегабалина и его энантиомера
MY158910A (en) Surface modified silicic acid semi-gels
MX339361B (es) Derivados de alternano.
UA110332C2 (uk) Застосування 2,3-дигідроксипропілдодеканоату для лікування себореї
UA115072C2 (uk) Похідні гідантоїну
MX2011011059A (es) Uso de propineb como repelente de aves.
EA201270390A1 (ru) 1,2,4-триазин, который может быть использован в качестве ускорителя вулканизации, и способ его получения